French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sezary syndrome and mycosis fungoides
January 13, 2020Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the French National Agency for Medicines and Health Product Safety (ANSM...Innate Pharma provides update from regulatory agencies on lacutamab TELLOMAK trial
January 9, 2020Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced a regulatory update regarding its TELLOMAK Phase II trial, evaluating the...The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia
January 2, 2020Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that the European Medicines Agency (EMA) has accepted the Marketing...Innate Pharma provides update on lacutamab TELLOMAK trial
December 13, 2019Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced an update regarding its TELLOMAK Phase II trial evaluating the efficacy and safety...Innate Pharma highlights FDA-approved Lumoxiti® at ASH 2019
December 8, 2019Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term follow-up data Innate Pharma SA (...Innate Pharma releases its financial calendar for 2020
December 4, 2019Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) today released its 2020 financial calendar: March 10, 2020: Publication of 2019 financial statements, with...
